AI Drug Discovery for Pharma and Biotech

Drug discovery

10

drugs

With orphan designations

Overview

Leigh syndrome is a genetically heterogeneous mitochondrial disorder characterized by neuroregression, symmetric brainstem/basal ganglia lesions, and impaired oxidative phosphorylation. Typically presenting in infancy with feeding difficulties, ataxia, and hypotonia, it progresses to respiratory failure, with most patients surviving <3 years [1][6][9]. Diagnosis requires clinical features plus biochemical/genetic evidence of mitochondrial dysfunction [1][9].

Population

  • Incidence: ~1:40,000 newborns, higher in genetic isolates (1:1,700 Faroe Islands) [1][2][9]

  • ~75% caused by nuclear DNA mutations (SURF1, PDHA1), 25% mitochondrial DNA (MT-ATP6) [6][9][19]

Burden

  • Mortality: 17% 2-year mortality in longitudinal studies, primarily from respiratory failure [4][14]

  • Functional decline: 57% wheelchair-dependent, 46% tube-fed by age 7.5 years [4][5]

  • High costs: Median 28 annual healthcare encounters, 65% requiring ICU care [7][16]

Therapies

  • Supportive care: seizure management (74% require AEDs), gastrostomy (46%), respiratory support [4][16]

  • Targeted interventions: ketogenic diet (PDH deficiency), thiamine/biotin (SLC19A3 variants) [3][8][13]

  • Experimental agents: EPI-743 (NCT01721733), cysteamine bitartrate under investigation [8][13]

Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases, rare ophthalmic disorders

Research Papers

491 drug discovery papers about Leigh syndrome, with 2 first-in-class and 20 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

491 drug discovery papers about Leigh syndrome, with 2 first-in-class and 20 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-29 | General anesthesia with remimazolam in a patient with leigh syndrome: a case report

Background: Leigh syndrome is a mitochondrial disorder in which impaired oxidative phosphorylation causes progressive neurologic damage. Brainstem lesions may cause central hypoventilation, apnea, and recurrent pulmonary infection, increasing perioperative risk.Case: We describe a patient with Leigh syndrome who had chronic central respiratory dysfunction, recurrent pneumonia, and a recent intensive care admission for sepsis and who subsequently underwent tracheostomy under general anesthesia. Anesthesia was induced and maintained with remimazolam and remifentanil. Hemodynamic parameters remained acceptable neuromuscular recovery, spontaneous ventilation remained inadequate, and the patient was returned to the intensive care unit with ventilatory support.Conclusion: In mitochondrial disease, propofol warrants careful consideration because of concerns regarding mitochondrial effects and propofol infusion syndrome. Remimazolam was selected based on severe respiratory vulnerability, recent multiorgan illness, and the anticipated need for postoperative ventilatory support, rather than as evidence of superiority over other agents.

Open article ↗



2026-09-23 | Inhibition of STING protects the neuroretina in an Ndufs4 knockout mouse model of mitochondrial complex 1 deficiency.

Ndufs4 encodes a key subunit of mitochondrial complex I, and its mutation causes NADH dehydrogenase deficiency associated with Leigh syndrome and Leber hereditary optic neuropathy. In Ndufs4 knockout (KO) mice, vision loss occurs alongside an "inflammatory wave" that disrupts neuroretinal function. In this study, we explore a novel inflammation-driven pathogenic mechanism and whether treatments targeting inflammatory pathways can mitigate neuroretina degeneration. Transcriptomic analysis of neuroretinal tissue from Ndufs4-KO mice identified immune-response activation as the most enriched pathway, with a twofold upregulation of stimulator of interferon genes (STING). Based on these findings, Ndufs4-KO mice received intraperitoneal injections of the STING inhibitors C-176 or SN-011 three times weekly from postnatal day 29 to 42; controls received vehicle only. Inflammatory cytokines were measured using ELISA, while retinal structure and function were evaluated through immunofluorescence and electroretinography (ERG). Immunofluorescence showed infiltration of Iba1-positive microglia into inner retinal layers of Ndufs4-KO mice, which was reduced by nearly 50% following C-176 and SN-011 treatment. ELISA confirmed decreased levels of the inflammatory markers CCL5 and ICAM-1. Untreated Ndufs4 retinas exhibited thinning of the inner retinal layers to about 83.3% of normal, whereas treated mice retained 89-90% of control thickness. ERG recordings demonstrated significantly improved retinal responses after STING inhibition. STING inhibition preserves neuroretina structure and function, highlighting its role in Ndufs4 pathology. This is the first study to show improved ERG responses following treatment in Ndufs4-KO mice, supporting STING as a promising therapeutic target for mitochondrial NADH dehydrogenase deficiency disorders.

Open article ↗



2026-09-03 | SLIRP differentially modulates RNA binding of pathogenic LRPPRC variants.

The LRPPRC/SLIRP complex is a key post-transcriptional regulator of mitochondrial gene expression, stabilizing mitochondrial mRNAs and promoting their polyadenylation and translation. Mutations in LRPPRC cause mitochondrial disorders, including Leigh syndrome French-Canadian type (LSFC), primarily affecting oxidative phosphorylation. Here, we examined the RNA-binding properties of wild-type LRPPRC and three pathogenic variants (A354V, K909del, and R1276_K1300del) using electrophoretic mobility shift assays, acoustic force spectroscopy, and AlphaFold 3 modeling. All three mutations reduced intrinsic RNA binding, with R1276_K1300del showing no detectable interaction in the absence of SLIRP. Remarkably, SLIRP restored RNA binding of this mutant to near wild-type levels, likely through conformational stabilization, as supported by single-molecule and structural analyses. These findings highlight SLIRP's critical role in modulating LRPPRC function and suggest that enhancing SLIRP activity represents a potential therapeutic strategy for LRPPRC-related mitochondrial disorders.

Open article ↗



2026-08-19 | Immune profiling and treatment cessation provide mechanistic insights into disease pathogenesis and considerations for translating pre-clinical strategies in Leigh syndrome

Abstract Genetic mitochondrial diseases (GMDs) are major challenges to human health accounting for a significant fraction of heritable neurologic diseases, myopathies, and inborn errors of metabolism. Leigh syndrome (LS) is the most common clinical presentation of GMD in pediatric patients. LS is a severe and complex disease for which effective clinical therapies are currently lacking. Preclinical therapies identified in the Ndufs4 (-/-) mouse model of LS include immune-targeting interventions and chronic mild hypoxia (11% oxygen). Immune-targeting interventions include rapamycin and high-dose pexidartinib, the latter appearing to fully suppress disease. The mechanisms underlying the benefits of hypoxia remain unclear, and the relationship between hypoxia and immune interventions have not been assessed. Here, we report the immune profile of brainstem of the Ndufs4 (-/-) mouse model prior to and after disease onset and the impact of pexidartinib treatment. We provide evidence that macrophages/monocytes drive pathology, consistent with recent genetic studies. We additionally find that pre-disease onset animals lack signs of inflammation, and that the elimination of leukocytes fully suppresses the molecular signature of disease. Finally, using distinct post-developmental periods of treatment, we find pexidartinib and rapamycin provide benefits which persist long beyond treatment cessation, while cessation of hypoxia results in rapid disease onset and an acceleration of disease progression. These findings are consistent with hypoxia acting upstream of immune cell activation and have major implications for the therapeutic translation of both hypoxia and immune targeting interventions. Our findings establish hypoxia-cessation as a novel method for synchronizing inflammatory disease onset in the Ndufs4 (-/-) model which will be useful in future mechanistic studies.

Open article ↗



2026-07-21 | Riboflavin therapy in complex I deficiency: Two new cases of leukoencephalopathy and a systematic literature review.

Complex I (CI) deficiency, the most common biochemical defect in pediatric mitochondrial diseases, presents with diverse phenotypes, including cardiomyopathy, myopathy, Leigh syndrome, and mitochondrial leukoencephalopathy (ML). No curative therapies exist. Riboflavin, a precursor of CI cofactors FMN and FAD, is a potential treatment, but evidence is heterogeneous and formal guidelines are lacking. We retrospectively analyzed two patients with genetically confirmed CI deficiency due to NDUFS1 and NDUFV2 variants, treated with high-dose riboflavin with long-term clinical, biochemical, neurophysiological and MRI follow-up (>16 years). A systematic literature review of riboflavin-responsive CI deficiency was also performed. Both patients presented with early acute psychomotor regression and extensive cavitating white matter lesions. Riboflavin (up to 10 mg/kg/day) was associated with rapid, near-complete neurological recovery, normalization of lactate and evoked potentials, and MRI improvement, stable in time. Our review identified 43 additional riboflavin-responsive CI cases, including cardiomyopathy (n = 16, largely due to ACAD9 variants), myopathy (n = 12, all ACAD9 variants), ML (n = 8, predominantly NDUFV1/NDUFV2 variants), Leigh syndrome (n = 5), MELAS-like presentations (n = 1), and optic atrophy (n = 1). Riboflavin may provide durable benefit across several CI-deficiency phenotypes. Beyond established efficacy in ACAD9-related cardiomyopathy, available evidence supports consideration of therapeutic trials in other phenotypes. Our two cases, supported by long-term follow-up and consistent instrumental data, provide further evidence supporting a potential benefit of riboflavin in ML, complementing eight earlier reports limited by short follow-up and sparse imaging. Variants affecting N-module subunits (NDUFV1, NDUFV2, NDUFS1), depending directly on FMN/FAD, may represent particularly suitable candidates for treatment. Prospective studies are warranted.

Open article ↗



proteins
2026-08-24 | Mitochondrial SUMOylation of NDUFA9 drives ClpP-dependent degradation and complex I dysfunction in a Leigh syndrome–associated mutation

Mitochondrial complex I (CI) dysfunction causes many inherited mitochondrial diseases, including Leigh syndrome, yet how post-translational modifications control CI subunit proteostasis remains unclear. Here we identify NDUFA9 as a mitochondrial SUMOylation substrate. SUMO1 conjugation at Lys370 promotes NDUFA9 binding to ClpP through the SIM motifs of ClpP and accelerates ClpP-dependent degradation. This destabilizes NDUFA9, reduces fully assembled CI and CI activity, and impairs mitochondrial bioenergetics. Mitochondrial SENP2 counteracts this process, defining a SUMO–SENP2–ClpP axis that preserves NDUFA9 and CI integrity. The Leigh syndrome–associated NDUFA9R321P mutation enhances Ubc9 binding, increases Lys370 SUMOylation, and drives excessive ClpP-dependent degradation. Preventing SUMOylation with the K370R substitution restores NDUFA9 abundance, CI integrity, and mitochondrial function. In systemic and brain-specific AAV replacement models, blocking SUMOylation also alleviates R321P-induced CI deficiency and motor dysfunction. These findings reveal aberrant NDUFA9 SUMOylation as a pathogenic mechanism in mitochondrial disease. The Leigh syndrome–associated R321P mutation drives excessive SUMOylation of NDUFA9, promoting ClpP-dependent degradation, weakening mitochondrial complex I, and causing mitochondrial and motor dysfunction.

Open article ↗



2025-09-19 | AMPD2 deficiency implicates cytosolic purine metabolism in the pathogenesis of Leigh syndrome

Abstract Importance Cellular mechanisms underlying mitochondrial dysfunction, a hallmark feature of many neurodegenerative conditions, remain incompletely understood, and their true diversity is unknown. Objective To identify and functionally validate novel genetic variants causative of Leigh syndrome. Design We performed whole genome sequencing (WGS) and first-degree relative genotyping on two unrelated adult subjects with brain MRI abnormalities evoking Leigh syndrome. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and respiratory chain enzymatic activity assays were performed to screen for respiratory complex assembly and/or oxidative phosphorylation impairments. Cells obtained from patient dermal and muscular biopsies were immortalized and later genetically corrected to evaluate cellular response to metabolic stress. Setting Subjects were recruited from The Neuro (McGill University), Rizk Hospital (Lebanese American University), and Centre Hospitalier Universitaire Sainte-Justine (University of Montreal). Research connections were established through the White Matter Rounds Network and GeneMatcher. Participants Four subjects representing three families with undiagnosed Leigh syndrome (age range 10-40 years) were ultimately recruited. Main outcome(s) and Measure(s) DNA sequencing uncovered a new autosomal recessive Leigh syndrome-associated gene that was functionally validated. Results Bi-allelic pathogenic variants in AMPD2 were detected in all subjects. BN-PAGE of patient skeletal muscle mitochondria captured an isolated complex V assembly defect in the context of heavy mTOR activation, while the accompanying enzymological assays reported decreased activities of complexes I and IV. Opposite to controls, patient-derived cell lines and muscle lacked AMPD2 protein, attributing null status to the variants detected. During metabolic challenge, only mutant cells suffered from mitochondrial hyperfusion and high-order cytosolic IMPDH2 oligomerization, implying simultaneous ATP accumulation and GTP deficiency. However, under these conditions, both complex V assembly and mTOR status in mutant cells and myotubes remained unchanged relative to the corrected lines. All mutant phenotypes observed collectively reverted upon exogenous introduction of wild-type AMPD2. Conclusions and Relevance The recognition of AMPD2 -related Leigh syndrome ( AMPD2 -LS) as a novel entity provides strong evidence for classifying AMPD2 deficiency as a mitochondrial disease. Our data suggest that respiratory capacity is significantly modulated by AMPD2, a cytosolic enzyme selectively regulating complex V assembly through an elusive process. Key points Question Do AMPD2 mutations cause mitochondrial disease? Findings In this case series, we found that four subjects from three families with molecularly unexplained Leigh syndrome carried bi-allelic, loss-of-function variants in AMPD2 , a gene not previously linked to mitochondrial disease. Biochemical analyses uncovered an isolated complex V assembly defect, providing diagnostic confirmation of a new entity: AMPD2 -related Leigh syndrome ( AMPD2 -LS). Meaning The cytosolic purine cycle is a primordial determinant of oxidative phosphorylation and mitochondrial health.

Open article ↗



2024-10-13 | Ndufs4 knockout mice with isolated complex I deficiency engage a futile adaptive brain response.

Paediatric Leigh syndrome (LS) is an early-onset and fatal neurodegenerative disorder lacking treatment options. LS is frequently caused by mutations in the NDUFS4 gene, encoding an accessory subunit of mitochondrial complex I (CI), the first complex of the oxidative phosphorylation (OXPHOS) system. Whole-body Ndufs4 knockout (KO) mice (WB-KO mice) are widely used to study isolated CI deficiency, LS pathology and interventions. These animals develop a brain-specific phenotype via an incompletely understood pathomechanism. Here we performed a quantitative analysis of the sub-brain proteome in six-weeks old WB-KO mice vs. wildtype (WT) mice. Brain regions comprised of a brain slice (BrSl), cerebellum (CB), cerebral cortex (CC), hippocampus (HC), inferior colliculus (IC), and superior colliculus (SC). Proteome analysis demonstrated similarities between CC/HC, and between IC/SC, whereas BrSl and CB differed from these two groups and each other. All brain regions displayed greatly reduced levels of two CI structural subunits (NDUFS4, NDUFA12) and an increased level of the CI assembly factor NDUFAF2. The level of CI-Q module subunits was significantly more reduced in IC/SC than in BrSl/CB/CC/HC, whereas other OXPHOS complex levels were not reduced. Gene ontology and pathway analysis demonstrated specific and common proteome changes between brain regions. Across brain regions, upregulation of cold-shock-associated proteins, mitochondrial fatty acid (FA) oxidation and synthesis (mtFAS) were the most prominent. FA-related pathways were predominantly upregulated in CB and HC. Based upon these results, we argue that stimulation of these pathways is futile and pro-pathological and discuss alternative strategies for therapeutic intervention in LS. SIGNIFICANCE: The Ndufs4 knockout mouse model is currently the most relevant and most widely used animal model to study the brain-linked pathophysiology of human Leigh Syndrome (LS) and intervention strategies. We demonstrate that the Ndufs4 knockout brain engages futile and pro-pathological responses. These responses explain both negative and positive outcomes of intervention studies in Leigh Syndrome mice and patients, thereby guiding novel intervention opportunities.

Open article ↗



2024-07-19 | Phenotypic Assessment of Cox10 Variants and their Implications for Leigh Syndrome

Objectives Cox10 is an enzyme required for the activity of cytochrome c oxidase. Humans who lack at least one functional copy of Cox10 have a form of Leigh Syndrome, a genetic disease that is usually fatal in infancy. As more human genomes are sequenced, new alleles are being discovered; whether or not these alleles encode functional proteins remains unclear. Thus, we set out to measure the phenotypes of many human Cox10 variants by expressing them in yeast cells. Results We successfully expressed the reference sequence and 25 variants of human Cox10 in yeast. We quantitated the ability of these variants to support growth on nonfermentable media and directly measured cytochrome c oxidase activity. 11 of these Cox10 variants supported approximately half or more the cytochrome c oxidase activity compared to the reference sequence. All of the strains containing those 11 variants also grew robustly using a nonfermentable carbon source. Cells expressing the other variants showed low cytochrome c oxidase activity and failed to grow on nonfermentable media.

Open article ↗



2024-07-18 | Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series.

Six percent of patients with Leigh syndrome (LS) present with infantile epileptic spasms syndrome (IESS). However, treatment strategies for IESS with LS remain unclear. This retrospective study aimed to evaluate the efficacy and safety of treatment strategies in patients with IESS complicated by LS and Leigh-like syndrome (LLS). We distributed questionnaires to 750 facilities in Japan, and the clinical data of 21 patients from 15 hospitals were collected. The data comprised treatment strategies, including adrenocorticotropic hormone (ACTH) therapy, ketogenic diet (KD) therapy, and antiseizure medications (ASMs); effectiveness of each treatment; and the adverse events. The median age at LS and LLS diagnosis was 7 months (range: 0 to 50), whereas that at the onset of epileptic spasms was 7 (range: 3 to 20). LS was diagnosed in 17 patients and LLS in four patients. Seven, two, five, and seven patients received ACTH + ASMs, ACTH + KD + ASMs, KD + ASMs, and ASMs only, respectively. Four (44%) of nine patients treated with ACTH and one (14%) of seven patients treated with KD achieved electroclinical remission within one month of treatment. No patients treated with only ASMs achieved electroclinical remission. Seven patients (33%) achieved electroclinical remission by the last follow-up. Adverse events were reported in four patients treated with ACTH, none treated with KD therapy, and eight treated with ASMs. ACTH therapy shows the best efficacy and rapid action in patients with IESS complicated by LS and LLS. The effectiveness of KD therapy and ASMs in this study was insufficient.

Open article ↗



gene therapies
2026-08-28 | Interim analysis of an international multi-site prospective natural history study evaluating the clinical presentation and progression of Leigh syndrome spectrum disorders.

Leigh Syndrome Spectrum (LSS) is the most common pediatric mitochondrial disease syndromic presentation. However, its natural history has not been well-characterized, particularly across diverse populations. Information obtained through robust, prospective natural history studies (NHSs) in LSS will be foundational to accurately counsel newly diagnosed families, develop effective therapeutics, and identify outcome measures for future clinical trials. We describe an ongoing multi-site, international, patient advocacy group funded, observational NHS in LSS. We employed a multi-site international federated design with local regulatory review coupled with central regulatory and coordinator support. To date, NHS outcome measures have been collected on LSS participants across 5 sites every 3 to 6 months for up to 3.8 years. Objective and subjective outcome measures were carefully selected by the international LSS outcome measure working group. Study data across sites were anonymized and combined for cleaning and analysis at the Data Coordinating Center (Children's Hospital of Philadelphia). Descriptive statistics of the study cohort and inter-measure correlations were analyzed across NHS assessments. Preliminary analysis of the first 74 participants was completed to characterize demographics, symptomatology, and clinical history. The average age at enrollment was 10.7 years, ranging from 0 to 50 years. The most common gene disorders were MT-ATP6 (22%, n=16), MT-ND5 (8%, n=6) and SURF1 (8%, n=6). No statistically significant between-group differences were detected by sex or genetic etiology. High inter-measure correlation between all the outcome measures and "gold standard" outcomes provides justification for future use of these assessments in both NHSs and clinical trials. We have demonstrated the feasibility of prospectively collecting robust international-site LSS NHS data through multi-site collaboration. These LSS community data will be critical for informing therapeutic development, outcome measure selection and clinical trial design, and providing baseline comparator evidence for development of future therapeutic interventions.

Open article ↗



2026-06-19 | Clinical Spectrum, Heteroplasmy-Phenotype Correlation, and Prognosis of the MT-ND3 m.10191 T > C Mutation.

To systematically characterize the phenotypic spectrum, neuroimaging features, heteroplasmy-phenotype correlation, and prognosis of the m.10191 T > C mutation. We collected and analyzed data from 52 patients (14 newly recruited; 38 from literature). Phenotypes were pre-classified as Leigh syndrome (LS), Leigh-like syndrome (LLS), MELAS/LS overlap syndrome, and MELAS-like syndrome. Neuroimaging data were subjected to statistical analysis to explore inter-lesional associations and lesion-symptom correlations. Heteroplasmy level underwent k-means clustering and latent class analysis (LCA) to define data-driven subgroups and model genotype-phenotype correlations. Prognostic factors were evaluated through Bayesian logistic regression, and survival analysis was conducted. The cohort exhibited phenotypic heterogeneity, dominated by LS (46.2%). Key features included epilepsy, developmental delay, and dystonia. Globus pallidus involvement frequently co-occurred with midbrain and pontine lesions. Heteroplasmy level differed significantly across phenotypes. LCA identified three classes corresponding to clinical phenotypes. High heteroplasmy level, medullary involvement, and severe hyperlactatemia were associated with disease progression. Survival analysis indicated a 5 year survival rate of 80.0%, with high heteroplasmy level, hypotonia, and cerebellar lesions predicting poorer survival. The m.10191 T > C mutation is linked to a continuous clinical spectrum correlated with heteroplasmy level. Specific clinical and neuroimaging features serve as valuable biomarkers for phenotypic classification and prognostic assessment.

Open article ↗



2026-03-15 | Leigh syndrome – review

Leigh syndrome is a rare, progressive mitochondrial disorder with onset typically in early infancy, characterized by severe neurodegeneration and high mortality. Its etiology is genetically heterogeneous and includes pathogenic variants in both mitochondrial and nuclear DNA, leading to impaired respiratory chain function and oxidative phosphorylation. The clinical phenotype encompasses a broad spectrum of neurological and systemic manifestations, with characteristic bilateral lesions of the basal ganglia and brainstem on magnetic resonance imaging serving as a key diagnostic feature. This review summarizes current knowledge on the pathogenesis, genotype–phenotype correlations, clinical features, and diagnostic approach in Leigh syndrome, with particular emphasis on the role of molecular genetic testing. The challenges and possibilities of genetic counseling and prenatal diagnosis, as well as current therapeutic strategies, are also discussed.

Open article ↗



2026-03-02 | New Neuroimaging Findings in Enoyl-CoA Hydratase Short-Chain 1 (ECHS1) Deficiency.

Enoyl-CoA hydratase short-chain 1 (ECHS1) variants are among the most common causes of Leigh syndrome. A five-year-old boy with ECHS1 deficiency initially presented with acute encephalopathy during the neonatal period. The patient had a high serum lactate level and a normal lactate/pyruvate ratio. Diffusion-weighted imaging showed reduced diffusion in the peri-rolandic subcortical white matter on day 3 and in the entire cortex and subcortical white matter on day 7. The patient subsequently presented with poor feeding, hypotonia, nystagmus, cerebellar ataxia, hearing loss, and strabismus. At one year of age, neuroimaging revealed reduced diffusion, hyperperfusion on arterial spin labeling, and increased lactate on magnetic resonance (MR) spectroscopy in the cerebellum. Cerebellar lesions have not previously been reported as imaging findings of ECHS1 deficiency except in one previous report of a patient with the same ECHS1 variant. Therefore, the ECHS1variant may specifically involve the cerebellum.

Open article ↗



2026-01-23 | Ultrasound-assisted gene therapy mitigates Leigh syndrome pathology.

Leigh syndrome (LS) is a fatal neurometabolic disease caused by mutations in genes involved in mitochondrial energy harvesting. While there is currently no cure for this disease, pre-clinical studies showed that gene therapy can afford a therapeutic benefit in a relevant model of LS, the Ndufs4-KO mouse. However, similar results need to be obtained using methods that can be translated in patients. Here, we combined two tools that are approved for clinical interventions. We used low-intensity focused ultrasound (FUS) to transiently permeabilize the blood-brain barrier and thereby facilitate the passage of an AAV9 vector. This approach resulted in transgene expression in the brain and peripheral organs. When applied to one-month old Ndufs4-KO mice, this gene replacement strategy significantly extended the survival of the animals and ameliorated brain and cardiac function. These improvements were associated with the restoration of protein expression and mitochondrial function. These findings support the potential of combining FUS with AAV-mediated gene delivery to treat LS and they warrant further clinical translation. This study also provides the first evidence that ultrasound-assisted gene replacement can exert a therapeutic effect in a condition affecting the central nervous system.

Open article ↗



cell therapies
2026-08-01 | Engineering mitochondrial delivery for efficient and precise mitochondrial transplantation

Mitochondrial dysfunction constitutes a shared pathological basis for a broad spectrum of major diseases, including primary mitochondrial disorders, neurodegenerative diseases, cardiovascular and cerebrovascular diseases, and agingassociated tissue degeneration [1].In inherited mitochondrial diseases, such as Leigh syndrome and mitochondrial DNA depletion syndromes, defects in mitochondrial DNA

Open article ↗



2026-05-25 | Metabolic Reprogramming and Exosome Remodeling in an Ndufs4 ‐Deficient Model of Leigh Syndrome

ABSTRACT Leigh syndrome is a severe neurometabolic disorder with an incompletely understood pathogenesis. This study investigated the role of Ndufs4 knockout in Leigh syndrome by exploring its impact on cellular metabolism and exosome biology. Initially, we observed that homozygous knockout ( Ndufs4 −/− ) mice exhibited significantly reduced body size and spleen weight compared to wild‐type ( Ndufs4 +/+ ) controls, although the spleen index remained unchanged. Notably, the brain index was significantly increased. Histological analysis revealed structural abnormalities in brain tissue, accompanied by elevated expression of the astrocytic marker GFAP, both in vivo and in differentiated neural stem cells (NSCs), indicating a neuropathological effect of Ndufs4 knockout. Metabolically, Ndufs4 knockout in NSCs did not reduce ATP levels but increased reactive oxygen species (ROS) levels, enhanced glucose uptake (2‐NBDG), and decreased mitochondrial membrane potential (JC‐1). Concurrent shifts in metabolites—decreased L‐lactate, increased acetyl‐CoA, and a lower NADP + /NADPH ratio—implied a potential redirection of metabolic flux toward the pentose phosphate pathway. Furthermore, although the total exosome concentration was reduced in Ndufs4 −/− mice, the protein content per exosome was significantly elevated, indicating enhanced protein loading per vesicle. Proteomic profiling of brain‐derived exosomes identified increased levels of flotillin‐1 and Slc6a5, proteins associated with the mTOR pathway. Consistent with this, downstream mTOR signaling (Phospho‐S6 Ribosomal Protein (Ser235/236; p‐RPS6) and Phospho‐p70 S6 kinase (Thr389; p‐p70S6K)) was substantially attenuated in Ndufs4 −/− mice, indicating suppression of the mTOR pathway. Together, these results elucidate novel mechanisms through which Ndufs4 knockout drives exosomal remodeling, reprograms cellular metabolism, and suppresses mTOR signaling, providing a conceptual framework for understanding Leigh syndrome pathogenesis and informing therapeutic development.

Open article ↗



2026-03-20 | Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models.

Mitochondrial transplantation holds significant potential for the treatment of mitochondrial diseases. However, how to efficiently deliver exogenous mitochondria to somatic cells or tissues remains unresolved. We present a mitochondrial transplantation approach to deliver mitochondria into the cells and tissues of mice and monkeys with high efficiency, based on encapsulating mitochondria with vesicles derived from the plasma membrane of erythrocytes. Treatment with encapsulated mitochondria complemented the loss, deletion, or mutation of mitochondrial DNA, thereby rescuing the associated bioenergetic and biochemical defects in patient-derived cells with mitochondrial disorders. Furthermore, mitochondrial capsules rescued the mitochondrial DNA depletion syndrome and Leigh syndrome in Dguok-/- and Ndufs4-/- mouse models, respectively. Moreover, in a mouse model of Parkinson's disease, mitochondrial capsules rescued neuron loss, improved motor skills, and restored mitochondrial function in the affected brain regions. Our study demonstrates the potential of this mitochondrial capsule as a treatment for mitochondrial disorders and proposes an "organelle therapy" strategy in regenerative medicine.

Open article ↗



2025-01-09 | [Study of the feasibility of polar body transfer combined with preimplantation genetic testing for blocking the intergenerational transmission of mitochondrial genetic diseases].

To assess the feasibility of first polar body transfer (PB1T) combined with preimplantation mitochondrial genetic testing for blocking the transmission of a pathogenic mitochondrial DNA 8993T>G mutation. A Chinese family affected with Leigh syndrome which had attended the Reproductive Medicine Centre of the First Affiliated Hospital of Anhui Medical University in September 2021 was selected as the study subject. Controlled ovarian hyperstimulation was carried out for the proband after completing the detection of the mitochondrial DNA 8993T>G mutation load among the pedigree members. Mature MII oocytes were inseminated by intracytoplasmic sperm injection (ICSI), cultured in vitro for 5 to 6 days to the blastocyst stage, and trophoblastocytes were obtained by microbiopsy. Mitochondrial DNA testing (PGT-MT) and chromosomal aneuploidy (PGT-A) analyses were carried out after whole-genome amplification, and the embryos with zero mutation load were selected for transfer. Amniotic fluid and umbilical cord blood samples were collected during middle pregnancy and after birth respectively for mitochondrial DNA testing to verify the reliability of embryo screening. As an attempt, PB1 with good morphology of MII oocytes was selected for transfer into the enucleated oocytoplasm from healthy donors, followed by ICSI fertilization, blastocyst culture and PGT of embryos using the same procedure. This study has been approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (No. 2021zhyx-B12). An antagonist protocol was used for ovarian stimulation, and a total of 19 oocytes were obtained, of which 14 MII were fertilized by ICSI, and 2 had developed into blastocysts. PGT-MT was carried out on biopsied trophoblastocytes, in which the mitochondrial DNA 8993T>G mutation load was not detected in one embryo, the other was 100% mutated, and the mutation loads of the remaining unfertilized eggs and developmentally arrested embryos ranged from 0% ~ 100%, presenting a clear biased distribution. With fully informed consent, one PGT-MT zero mutation load blastocyst was transferred and clinical pregnancy was achieved. Mitochondrial DNA and chromosomal testing of amniotic fluid cells during middle pregnancy had revealed no abnormalities. The proband had delivered a healthy boy through Caesarean section at 39+5 weeks of gestation, and no mutation was detected in the cord blood sample. Five well-formed PBs from 14 eggs were selected for PB1 transfer, followed by ICSI and culture, and two of the reconstituted embryos had formed blastocysts, with none of the above mutations detected in the biopsied samples. The PGT-MT technology can help families affected with mitochondrial diseases to have healthy offspring. PB1 transfer in combination with ICSI and PGT-MT holds the promise of turning waste into treasure and providing an alternative means of fertility for such families.

Open article ↗



2024-09-03 | Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome.

Mitochondria transfer is a recently described phenomenon in which donor cells deliver mitochondria to acceptor cells1-3. One possible consequence of mitochondria transfer is energetic support of neighbouring cells; for example, exogenous healthy mitochondria can rescue cell-intrinsic defects in mitochondrial metabolism in cultured ρ0 cells or Ndufs4-/- peritoneal macrophages4-7. Exposing haematopoietic stem cells to purified mitochondria before autologous haematopoietic stem cell transplantation allowed for treatment of anaemia in patients with large-scale mitochondrial DNA mutations8,9, and mitochondria transplantation was shown to minimize ischaemic damage to the heart10-12, brain13-15 and limbs16. However, the therapeutic potential of using mitochondria transfer-based therapies to treat inherited mitochondrial diseases is unclear. Here we demonstrate improved morbidity and mortality of the Ndufs4-/- mouse model of Leigh syndrome (LS) in multiple treatment paradigms associated with mitochondria transfer. Transplantation of bone marrow from wild-type mice, which is associated with release of haematopoietic cell-derived extracellular mitochondria into circulation and transfer of mitochondria to host cells in multiple organs, ameliorates LS in mice. Furthermore, administering isolated mitochondria from wild-type mice extends lifespan, improves neurological function and increases energy expenditure of Ndufs4-/- mice, whereas mitochondria from Ndufs4-/- mice did not improve neurological function. Finally, we demonstrate that cross-species administration of human mitochondria to Ndufs4-/- mice also improves LS. These data suggest that mitochondria transfer-related approaches can be harnessed to treat mitochondrial diseases, such as LS.

Open article ↗



other
2026-02-04 | Leigh Syndrome Pathomechanism Involves Region-Specific Innate Immune Activation in Ndufs4 Knockout Mice.

Although recent evidence suggests that the immune system contributes to the pathogenesis of paediatric Leigh syndrome, detailed mechanistic insights are still lacking. Here, we investigated the involvement of immune system activation and inflammation in brain tissue in Leigh syndrome, using hypothesis generating methods. We compared the transcriptomes of olfactory bulb and cerebellum from male Ndufs4−/− (knockout) mice (n = 5–6), a well-established model of paediatric Leigh syndrome. Relative to wildtype animals, knockout mice displayed enrichment of innate immune system pathways in the olfactory bulb. Unexpectedly, relative to the olfactory bulb, few pathways were enriched in the cerebellum, and none that indicated similar changes to the immune system. Innate immune system pathways in the olfactory bulb were mainly upregulated and included a large set of interferon stimulated genes, and genes involved in JAK-STAT and retinoic acid-inducible gene 1-like signalling, interleukins, interferon receptors and endogenous double strand RNA sensors. We propose that innate immune system activation starts in the olfactory bulb, is mediated by the retinoic acid-inducible gene 1-like signalling pathway in response to increased cytosolic double-strand RNA, leading to chemokines that recruit leukocytes to other brain regions to elicit an immune response. Our results fill in the gap between mitochondrial dysfunction and activation of the innate immune response, which has been reported by others. Our findings strongly suggest that immune system activation constitutes part of the Leigh syndrome pathomechanism, which is compatible with the improvement observed in mitochondrial disease patients following immune system-targeting interventions.

Open article ↗



2024-04-29 | Interferon-gamma contributes to disease progression in the Ndufs4(-/-) model of Leigh syndrome.

Leigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi-system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the Ndufs4(-/-) mouse model of LS: treatment of Ndufs4(-/-) mice with the macrophage-depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon-gamma (IFNγ) and interferon gamma-induced protein 10 (IP10) were found to be significantly elevated in Ndufs4(-/-) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS. To establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient Ndufs4(-/-)/Ifng(-/-) and Ndufs4(-/-)/IP10(-/-) double knockout animals, as well as IFNγ and IP10 heterozygous, Ndufs4(-/-)/Ifng(+/-) and Ndufs4(-/-)/IP10(+/-), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS. Loss of IP10 does not significantly impact the onset or progression of disease in the Ndufs4(-/-) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage-dependent manner, though the benefits are modest compared to Csf1r inhibition. IFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.

Open article ↗



2023-07-10 | IFNγ modestly contributes to disease progression in theNdufs4(-/-) model of Leigh syndrome while IP10 is dispensable

Abstract Leigh syndrome (LS) is the most common pediatric presentation of genetic mitochondrial disease. LS is a multi-system disease characterized by severe neurologic and metabolic abnormalities. The defining feature of the disease is the presence of symmetric, bilateral, progressive necrotizing lesions in the brain stem, cerebellum, and basal ganglia. The pathogenic mechanisms underlying disease initiation and progression in LS have yet to be elucidated. Recent evidence demonstrates that the immune system plays a key role in LS pathogenesis. Treatment with the macrophage-depleting Csf1r inhibitor pexidartinib prevents disease in the Ndufs4 (-/-) mouse model of LS, but the mechanisms leading to immune activation and governing disease progression remain to be elucidated. In recent work, the cytokines IFNγ and IFNγ-induced protein 10 (IP10) were found to be significantly elevated in Ndufs4 (-/-) brainstem. Given their role as macrophage-activating factors, here we sought to assess the role of IFNγ and IP10 in LS using by generating Ndufs4 (-/-)/ Ifng (-/-) and Ndufs4 (-/-)/ IP10 (-/-) double knockout lines. We find that IP10 alone does not significantly impact the onset or progression of disease in the Ndufs4 (-/-) model, while IFNγ loss significantly, but modestly, improves survival. These data indicate that IFNγ contributes to pathology, but that IFNγ and IP10 are both dispensable for overall disease course of LS. Our findings support some role for IFNγ targeting therapies in the management of mitochondrial disease, but suggest they may provide only modest benefits, at least in LS.

Open article ↗



2023-02-03 | PET117 Modulates Mitochondrial-encoded COX1 Translation by stabilizing TACO1

Abstract Mitochondria are the most important organelles in energy metabolism. Complexes of the mitochondrial oxidative phosphorylation system (OXPHOS) are formed by proteins of dual origin synthesized in the cytosol or mitochondria. The mechanisms underlying specific translation by mitoribosomes in mammals are largely unknown. Here, we report a chaperone protein of cytochrome c oxidase (COX) assembly, PET117 plays a critical role in the synthesis of mitochondrial-encoded COX1 protein in human cells. Lack of PET117 impaired mitochondrial function via suppression of mitochondrial oxygen consumption rate (OCR), probably due to reduced stability of TACO1, a COX1 translational activator. We uncovered the role of PET117 in mitochondrial regulation and a novel PET117-TACO1 axis modulating mitochondrial gene expression.

Open article ↗



2022-09-08 | The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence.

Genetic mitochondrial diseases represent a significant challenge to human health. These diseases are extraordinarily heterogeneous in clinical presentation and genetic origin, and often involve multi-system disease with severe progressive symptoms. Mitochondrial diseases represent the most common cause of inherited metabolic disorders and one of the most common causes of inherited neurologic diseases, yet no proven therapeutic strategies yet exist. The basic cell and molecular mechanisms underlying the pathogenesis of mitochondrial diseases have not been resolved, hampering efforts to develop therapeutic agents. In recent pre-clinical work, we have shown that pharmacologic agents targeting the immune system can prevent disease in the Ndufs4(KO) model of Leigh syndrome, indicating that the immune system plays a causal role in the pathogenesis of at least this form of mitochondrial disease. Intriguingly, a number of case reports have indicated that immune-targeting therapeutics may be beneficial in the setting of genetic mitochondrial disease. Here, we summarize clinical and pre-clinical evidence suggesting a key role for the immune system in mediating the pathogenesis of at least some forms of genetic mitochondrial disease. Significant clinical and pre-clinical evidence indicates a key role for the immune system as a significant in the pathogenesis of at least some forms of genetic mitochondrial disease.

Open article ↗



small molecules
2026-09-29 | General anesthesia with remimazolam in a patient with leigh syndrome: a case report

Background: Leigh syndrome is a mitochondrial disorder in which impaired oxidative phosphorylation causes progressive neurologic damage. Brainstem lesions may cause central hypoventilation, apnea, and recurrent pulmonary infection, increasing perioperative risk.Case: We describe a patient with Leigh syndrome who had chronic central respiratory dysfunction, recurrent pneumonia, and a recent intensive care admission for sepsis and who subsequently underwent tracheostomy under general anesthesia. Anesthesia was induced and maintained with remimazolam and remifentanil. Hemodynamic parameters remained acceptable neuromuscular recovery, spontaneous ventilation remained inadequate, and the patient was returned to the intensive care unit with ventilatory support.Conclusion: In mitochondrial disease, propofol warrants careful consideration because of concerns regarding mitochondrial effects and propofol infusion syndrome. Remimazolam was selected based on severe respiratory vulnerability, recent multiorgan illness, and the anticipated need for postoperative ventilatory support, rather than as evidence of superiority over other agents.

Open article ↗



2026-09-23 | Inhibition of STING protects the neuroretina in an Ndufs4 knockout mouse model of mitochondrial complex 1 deficiency.

Ndufs4 encodes a key subunit of mitochondrial complex I, and its mutation causes NADH dehydrogenase deficiency associated with Leigh syndrome and Leber hereditary optic neuropathy. In Ndufs4 knockout (KO) mice, vision loss occurs alongside an "inflammatory wave" that disrupts neuroretinal function. In this study, we explore a novel inflammation-driven pathogenic mechanism and whether treatments targeting inflammatory pathways can mitigate neuroretina degeneration. Transcriptomic analysis of neuroretinal tissue from Ndufs4-KO mice identified immune-response activation as the most enriched pathway, with a twofold upregulation of stimulator of interferon genes (STING). Based on these findings, Ndufs4-KO mice received intraperitoneal injections of the STING inhibitors C-176 or SN-011 three times weekly from postnatal day 29 to 42; controls received vehicle only. Inflammatory cytokines were measured using ELISA, while retinal structure and function were evaluated through immunofluorescence and electroretinography (ERG). Immunofluorescence showed infiltration of Iba1-positive microglia into inner retinal layers of Ndufs4-KO mice, which was reduced by nearly 50% following C-176 and SN-011 treatment. ELISA confirmed decreased levels of the inflammatory markers CCL5 and ICAM-1. Untreated Ndufs4 retinas exhibited thinning of the inner retinal layers to about 83.3% of normal, whereas treated mice retained 89-90% of control thickness. ERG recordings demonstrated significantly improved retinal responses after STING inhibition. STING inhibition preserves neuroretina structure and function, highlighting its role in Ndufs4 pathology. This is the first study to show improved ERG responses following treatment in Ndufs4-KO mice, supporting STING as a promising therapeutic target for mitochondrial NADH dehydrogenase deficiency disorders.

Open article ↗



2026-09-03 | SLIRP differentially modulates RNA binding of pathogenic LRPPRC variants.

The LRPPRC/SLIRP complex is a key post-transcriptional regulator of mitochondrial gene expression, stabilizing mitochondrial mRNAs and promoting their polyadenylation and translation. Mutations in LRPPRC cause mitochondrial disorders, including Leigh syndrome French-Canadian type (LSFC), primarily affecting oxidative phosphorylation. Here, we examined the RNA-binding properties of wild-type LRPPRC and three pathogenic variants (A354V, K909del, and R1276_K1300del) using electrophoretic mobility shift assays, acoustic force spectroscopy, and AlphaFold 3 modeling. All three mutations reduced intrinsic RNA binding, with R1276_K1300del showing no detectable interaction in the absence of SLIRP. Remarkably, SLIRP restored RNA binding of this mutant to near wild-type levels, likely through conformational stabilization, as supported by single-molecule and structural analyses. These findings highlight SLIRP's critical role in modulating LRPPRC function and suggest that enhancing SLIRP activity represents a potential therapeutic strategy for LRPPRC-related mitochondrial disorders.

Open article ↗



2026-08-19 | Immune profiling and treatment cessation provide mechanistic insights into disease pathogenesis and considerations for translating pre-clinical strategies in Leigh syndrome

Abstract Genetic mitochondrial diseases (GMDs) are major challenges to human health accounting for a significant fraction of heritable neurologic diseases, myopathies, and inborn errors of metabolism. Leigh syndrome (LS) is the most common clinical presentation of GMD in pediatric patients. LS is a severe and complex disease for which effective clinical therapies are currently lacking. Preclinical therapies identified in the Ndufs4 (-/-) mouse model of LS include immune-targeting interventions and chronic mild hypoxia (11% oxygen). Immune-targeting interventions include rapamycin and high-dose pexidartinib, the latter appearing to fully suppress disease. The mechanisms underlying the benefits of hypoxia remain unclear, and the relationship between hypoxia and immune interventions have not been assessed. Here, we report the immune profile of brainstem of the Ndufs4 (-/-) mouse model prior to and after disease onset and the impact of pexidartinib treatment. We provide evidence that macrophages/monocytes drive pathology, consistent with recent genetic studies. We additionally find that pre-disease onset animals lack signs of inflammation, and that the elimination of leukocytes fully suppresses the molecular signature of disease. Finally, using distinct post-developmental periods of treatment, we find pexidartinib and rapamycin provide benefits which persist long beyond treatment cessation, while cessation of hypoxia results in rapid disease onset and an acceleration of disease progression. These findings are consistent with hypoxia acting upstream of immune cell activation and have major implications for the therapeutic translation of both hypoxia and immune targeting interventions. Our findings establish hypoxia-cessation as a novel method for synchronizing inflammatory disease onset in the Ndufs4 (-/-) model which will be useful in future mechanistic studies.

Open article ↗



2026-07-21 | Riboflavin therapy in complex I deficiency: Two new cases of leukoencephalopathy and a systematic literature review.

Complex I (CI) deficiency, the most common biochemical defect in pediatric mitochondrial diseases, presents with diverse phenotypes, including cardiomyopathy, myopathy, Leigh syndrome, and mitochondrial leukoencephalopathy (ML). No curative therapies exist. Riboflavin, a precursor of CI cofactors FMN and FAD, is a potential treatment, but evidence is heterogeneous and formal guidelines are lacking. We retrospectively analyzed two patients with genetically confirmed CI deficiency due to NDUFS1 and NDUFV2 variants, treated with high-dose riboflavin with long-term clinical, biochemical, neurophysiological and MRI follow-up (>16 years). A systematic literature review of riboflavin-responsive CI deficiency was also performed. Both patients presented with early acute psychomotor regression and extensive cavitating white matter lesions. Riboflavin (up to 10 mg/kg/day) was associated with rapid, near-complete neurological recovery, normalization of lactate and evoked potentials, and MRI improvement, stable in time. Our review identified 43 additional riboflavin-responsive CI cases, including cardiomyopathy (n = 16, largely due to ACAD9 variants), myopathy (n = 12, all ACAD9 variants), ML (n = 8, predominantly NDUFV1/NDUFV2 variants), Leigh syndrome (n = 5), MELAS-like presentations (n = 1), and optic atrophy (n = 1). Riboflavin may provide durable benefit across several CI-deficiency phenotypes. Beyond established efficacy in ACAD9-related cardiomyopathy, available evidence supports consideration of therapeutic trials in other phenotypes. Our two cases, supported by long-term follow-up and consistent instrumental data, provide further evidence supporting a potential benefit of riboflavin in ML, complementing eight earlier reports limited by short follow-up and sparse imaging. Variants affecting N-module subunits (NDUFV1, NDUFV2, NDUFS1), depending directly on FMN/FAD, may represent particularly suitable candidates for treatment. Prospective studies are warranted.

Open article ↗



proteins
2026-08-24 | Mitochondrial SUMOylation of NDUFA9 drives ClpP-dependent degradation and complex I dysfunction in a Leigh syndrome–associated mutation

Mitochondrial complex I (CI) dysfunction causes many inherited mitochondrial diseases, including Leigh syndrome, yet how post-translational modifications control CI subunit proteostasis remains unclear. Here we identify NDUFA9 as a mitochondrial SUMOylation substrate. SUMO1 conjugation at Lys370 promotes NDUFA9 binding to ClpP through the SIM motifs of ClpP and accelerates ClpP-dependent degradation. This destabilizes NDUFA9, reduces fully assembled CI and CI activity, and impairs mitochondrial bioenergetics. Mitochondrial SENP2 counteracts this process, defining a SUMO–SENP2–ClpP axis that preserves NDUFA9 and CI integrity. The Leigh syndrome–associated NDUFA9R321P mutation enhances Ubc9 binding, increases Lys370 SUMOylation, and drives excessive ClpP-dependent degradation. Preventing SUMOylation with the K370R substitution restores NDUFA9 abundance, CI integrity, and mitochondrial function. In systemic and brain-specific AAV replacement models, blocking SUMOylation also alleviates R321P-induced CI deficiency and motor dysfunction. These findings reveal aberrant NDUFA9 SUMOylation as a pathogenic mechanism in mitochondrial disease. The Leigh syndrome–associated R321P mutation drives excessive SUMOylation of NDUFA9, promoting ClpP-dependent degradation, weakening mitochondrial complex I, and causing mitochondrial and motor dysfunction.

Open article ↗



2025-09-19 | AMPD2 deficiency implicates cytosolic purine metabolism in the pathogenesis of Leigh syndrome

Abstract Importance Cellular mechanisms underlying mitochondrial dysfunction, a hallmark feature of many neurodegenerative conditions, remain incompletely understood, and their true diversity is unknown. Objective To identify and functionally validate novel genetic variants causative of Leigh syndrome. Design We performed whole genome sequencing (WGS) and first-degree relative genotyping on two unrelated adult subjects with brain MRI abnormalities evoking Leigh syndrome. Blue native polyacrylamide gel electrophoresis (BN-PAGE) and respiratory chain enzymatic activity assays were performed to screen for respiratory complex assembly and/or oxidative phosphorylation impairments. Cells obtained from patient dermal and muscular biopsies were immortalized and later genetically corrected to evaluate cellular response to metabolic stress. Setting Subjects were recruited from The Neuro (McGill University), Rizk Hospital (Lebanese American University), and Centre Hospitalier Universitaire Sainte-Justine (University of Montreal). Research connections were established through the White Matter Rounds Network and GeneMatcher. Participants Four subjects representing three families with undiagnosed Leigh syndrome (age range 10-40 years) were ultimately recruited. Main outcome(s) and Measure(s) DNA sequencing uncovered a new autosomal recessive Leigh syndrome-associated gene that was functionally validated. Results Bi-allelic pathogenic variants in AMPD2 were detected in all subjects. BN-PAGE of patient skeletal muscle mitochondria captured an isolated complex V assembly defect in the context of heavy mTOR activation, while the accompanying enzymological assays reported decreased activities of complexes I and IV. Opposite to controls, patient-derived cell lines and muscle lacked AMPD2 protein, attributing null status to the variants detected. During metabolic challenge, only mutant cells suffered from mitochondrial hyperfusion and high-order cytosolic IMPDH2 oligomerization, implying simultaneous ATP accumulation and GTP deficiency. However, under these conditions, both complex V assembly and mTOR status in mutant cells and myotubes remained unchanged relative to the corrected lines. All mutant phenotypes observed collectively reverted upon exogenous introduction of wild-type AMPD2. Conclusions and Relevance The recognition of AMPD2 -related Leigh syndrome ( AMPD2 -LS) as a novel entity provides strong evidence for classifying AMPD2 deficiency as a mitochondrial disease. Our data suggest that respiratory capacity is significantly modulated by AMPD2, a cytosolic enzyme selectively regulating complex V assembly through an elusive process. Key points Question Do AMPD2 mutations cause mitochondrial disease? Findings In this case series, we found that four subjects from three families with molecularly unexplained Leigh syndrome carried bi-allelic, loss-of-function variants in AMPD2 , a gene not previously linked to mitochondrial disease. Biochemical analyses uncovered an isolated complex V assembly defect, providing diagnostic confirmation of a new entity: AMPD2 -related Leigh syndrome ( AMPD2 -LS). Meaning The cytosolic purine cycle is a primordial determinant of oxidative phosphorylation and mitochondrial health.

Open article ↗



2024-10-13 | Ndufs4 knockout mice with isolated complex I deficiency engage a futile adaptive brain response.

Paediatric Leigh syndrome (LS) is an early-onset and fatal neurodegenerative disorder lacking treatment options. LS is frequently caused by mutations in the NDUFS4 gene, encoding an accessory subunit of mitochondrial complex I (CI), the first complex of the oxidative phosphorylation (OXPHOS) system. Whole-body Ndufs4 knockout (KO) mice (WB-KO mice) are widely used to study isolated CI deficiency, LS pathology and interventions. These animals develop a brain-specific phenotype via an incompletely understood pathomechanism. Here we performed a quantitative analysis of the sub-brain proteome in six-weeks old WB-KO mice vs. wildtype (WT) mice. Brain regions comprised of a brain slice (BrSl), cerebellum (CB), cerebral cortex (CC), hippocampus (HC), inferior colliculus (IC), and superior colliculus (SC). Proteome analysis demonstrated similarities between CC/HC, and between IC/SC, whereas BrSl and CB differed from these two groups and each other. All brain regions displayed greatly reduced levels of two CI structural subunits (NDUFS4, NDUFA12) and an increased level of the CI assembly factor NDUFAF2. The level of CI-Q module subunits was significantly more reduced in IC/SC than in BrSl/CB/CC/HC, whereas other OXPHOS complex levels were not reduced. Gene ontology and pathway analysis demonstrated specific and common proteome changes between brain regions. Across brain regions, upregulation of cold-shock-associated proteins, mitochondrial fatty acid (FA) oxidation and synthesis (mtFAS) were the most prominent. FA-related pathways were predominantly upregulated in CB and HC. Based upon these results, we argue that stimulation of these pathways is futile and pro-pathological and discuss alternative strategies for therapeutic intervention in LS. SIGNIFICANCE: The Ndufs4 knockout mouse model is currently the most relevant and most widely used animal model to study the brain-linked pathophysiology of human Leigh Syndrome (LS) and intervention strategies. We demonstrate that the Ndufs4 knockout brain engages futile and pro-pathological responses. These responses explain both negative and positive outcomes of intervention studies in Leigh Syndrome mice and patients, thereby guiding novel intervention opportunities.

Open article ↗



2024-07-19 | Phenotypic Assessment of Cox10 Variants and their Implications for Leigh Syndrome

Objectives Cox10 is an enzyme required for the activity of cytochrome c oxidase. Humans who lack at least one functional copy of Cox10 have a form of Leigh Syndrome, a genetic disease that is usually fatal in infancy. As more human genomes are sequenced, new alleles are being discovered; whether or not these alleles encode functional proteins remains unclear. Thus, we set out to measure the phenotypes of many human Cox10 variants by expressing them in yeast cells. Results We successfully expressed the reference sequence and 25 variants of human Cox10 in yeast. We quantitated the ability of these variants to support growth on nonfermentable media and directly measured cytochrome c oxidase activity. 11 of these Cox10 variants supported approximately half or more the cytochrome c oxidase activity compared to the reference sequence. All of the strains containing those 11 variants also grew robustly using a nonfermentable carbon source. Cells expressing the other variants showed low cytochrome c oxidase activity and failed to grow on nonfermentable media.

Open article ↗



2024-07-18 | Infantile Epileptic Spasms Syndrome Complicated by Leigh Syndrome and Leigh-Like Syndrome: A Retrospective, Nationwide, Multicenter Case Series.

Six percent of patients with Leigh syndrome (LS) present with infantile epileptic spasms syndrome (IESS). However, treatment strategies for IESS with LS remain unclear. This retrospective study aimed to evaluate the efficacy and safety of treatment strategies in patients with IESS complicated by LS and Leigh-like syndrome (LLS). We distributed questionnaires to 750 facilities in Japan, and the clinical data of 21 patients from 15 hospitals were collected. The data comprised treatment strategies, including adrenocorticotropic hormone (ACTH) therapy, ketogenic diet (KD) therapy, and antiseizure medications (ASMs); effectiveness of each treatment; and the adverse events. The median age at LS and LLS diagnosis was 7 months (range: 0 to 50), whereas that at the onset of epileptic spasms was 7 (range: 3 to 20). LS was diagnosed in 17 patients and LLS in four patients. Seven, two, five, and seven patients received ACTH + ASMs, ACTH + KD + ASMs, KD + ASMs, and ASMs only, respectively. Four (44%) of nine patients treated with ACTH and one (14%) of seven patients treated with KD achieved electroclinical remission within one month of treatment. No patients treated with only ASMs achieved electroclinical remission. Seven patients (33%) achieved electroclinical remission by the last follow-up. Adverse events were reported in four patients treated with ACTH, none treated with KD therapy, and eight treated with ASMs. ACTH therapy shows the best efficacy and rapid action in patients with IESS complicated by LS and LLS. The effectiveness of KD therapy and ASMs in this study was insufficient.

Open article ↗



gene therapies
2026-08-28 | Interim analysis of an international multi-site prospective natural history study evaluating the clinical presentation and progression of Leigh syndrome spectrum disorders.

Leigh Syndrome Spectrum (LSS) is the most common pediatric mitochondrial disease syndromic presentation. However, its natural history has not been well-characterized, particularly across diverse populations. Information obtained through robust, prospective natural history studies (NHSs) in LSS will be foundational to accurately counsel newly diagnosed families, develop effective therapeutics, and identify outcome measures for future clinical trials. We describe an ongoing multi-site, international, patient advocacy group funded, observational NHS in LSS. We employed a multi-site international federated design with local regulatory review coupled with central regulatory and coordinator support. To date, NHS outcome measures have been collected on LSS participants across 5 sites every 3 to 6 months for up to 3.8 years. Objective and subjective outcome measures were carefully selected by the international LSS outcome measure working group. Study data across sites were anonymized and combined for cleaning and analysis at the Data Coordinating Center (Children's Hospital of Philadelphia). Descriptive statistics of the study cohort and inter-measure correlations were analyzed across NHS assessments. Preliminary analysis of the first 74 participants was completed to characterize demographics, symptomatology, and clinical history. The average age at enrollment was 10.7 years, ranging from 0 to 50 years. The most common gene disorders were MT-ATP6 (22%, n=16), MT-ND5 (8%, n=6) and SURF1 (8%, n=6). No statistically significant between-group differences were detected by sex or genetic etiology. High inter-measure correlation between all the outcome measures and "gold standard" outcomes provides justification for future use of these assessments in both NHSs and clinical trials. We have demonstrated the feasibility of prospectively collecting robust international-site LSS NHS data through multi-site collaboration. These LSS community data will be critical for informing therapeutic development, outcome measure selection and clinical trial design, and providing baseline comparator evidence for development of future therapeutic interventions.

Open article ↗



2026-06-19 | Clinical Spectrum, Heteroplasmy-Phenotype Correlation, and Prognosis of the MT-ND3 m.10191 T > C Mutation.

To systematically characterize the phenotypic spectrum, neuroimaging features, heteroplasmy-phenotype correlation, and prognosis of the m.10191 T > C mutation. We collected and analyzed data from 52 patients (14 newly recruited; 38 from literature). Phenotypes were pre-classified as Leigh syndrome (LS), Leigh-like syndrome (LLS), MELAS/LS overlap syndrome, and MELAS-like syndrome. Neuroimaging data were subjected to statistical analysis to explore inter-lesional associations and lesion-symptom correlations. Heteroplasmy level underwent k-means clustering and latent class analysis (LCA) to define data-driven subgroups and model genotype-phenotype correlations. Prognostic factors were evaluated through Bayesian logistic regression, and survival analysis was conducted. The cohort exhibited phenotypic heterogeneity, dominated by LS (46.2%). Key features included epilepsy, developmental delay, and dystonia. Globus pallidus involvement frequently co-occurred with midbrain and pontine lesions. Heteroplasmy level differed significantly across phenotypes. LCA identified three classes corresponding to clinical phenotypes. High heteroplasmy level, medullary involvement, and severe hyperlactatemia were associated with disease progression. Survival analysis indicated a 5 year survival rate of 80.0%, with high heteroplasmy level, hypotonia, and cerebellar lesions predicting poorer survival. The m.10191 T > C mutation is linked to a continuous clinical spectrum correlated with heteroplasmy level. Specific clinical and neuroimaging features serve as valuable biomarkers for phenotypic classification and prognostic assessment.

Open article ↗



2026-03-15 | Leigh syndrome – review

Leigh syndrome is a rare, progressive mitochondrial disorder with onset typically in early infancy, characterized by severe neurodegeneration and high mortality. Its etiology is genetically heterogeneous and includes pathogenic variants in both mitochondrial and nuclear DNA, leading to impaired respiratory chain function and oxidative phosphorylation. The clinical phenotype encompasses a broad spectrum of neurological and systemic manifestations, with characteristic bilateral lesions of the basal ganglia and brainstem on magnetic resonance imaging serving as a key diagnostic feature. This review summarizes current knowledge on the pathogenesis, genotype–phenotype correlations, clinical features, and diagnostic approach in Leigh syndrome, with particular emphasis on the role of molecular genetic testing. The challenges and possibilities of genetic counseling and prenatal diagnosis, as well as current therapeutic strategies, are also discussed.

Open article ↗



2026-03-02 | New Neuroimaging Findings in Enoyl-CoA Hydratase Short-Chain 1 (ECHS1) Deficiency.

Enoyl-CoA hydratase short-chain 1 (ECHS1) variants are among the most common causes of Leigh syndrome. A five-year-old boy with ECHS1 deficiency initially presented with acute encephalopathy during the neonatal period. The patient had a high serum lactate level and a normal lactate/pyruvate ratio. Diffusion-weighted imaging showed reduced diffusion in the peri-rolandic subcortical white matter on day 3 and in the entire cortex and subcortical white matter on day 7. The patient subsequently presented with poor feeding, hypotonia, nystagmus, cerebellar ataxia, hearing loss, and strabismus. At one year of age, neuroimaging revealed reduced diffusion, hyperperfusion on arterial spin labeling, and increased lactate on magnetic resonance (MR) spectroscopy in the cerebellum. Cerebellar lesions have not previously been reported as imaging findings of ECHS1 deficiency except in one previous report of a patient with the same ECHS1 variant. Therefore, the ECHS1variant may specifically involve the cerebellum.

Open article ↗



2026-01-23 | Ultrasound-assisted gene therapy mitigates Leigh syndrome pathology.

Leigh syndrome (LS) is a fatal neurometabolic disease caused by mutations in genes involved in mitochondrial energy harvesting. While there is currently no cure for this disease, pre-clinical studies showed that gene therapy can afford a therapeutic benefit in a relevant model of LS, the Ndufs4-KO mouse. However, similar results need to be obtained using methods that can be translated in patients. Here, we combined two tools that are approved for clinical interventions. We used low-intensity focused ultrasound (FUS) to transiently permeabilize the blood-brain barrier and thereby facilitate the passage of an AAV9 vector. This approach resulted in transgene expression in the brain and peripheral organs. When applied to one-month old Ndufs4-KO mice, this gene replacement strategy significantly extended the survival of the animals and ameliorated brain and cardiac function. These improvements were associated with the restoration of protein expression and mitochondrial function. These findings support the potential of combining FUS with AAV-mediated gene delivery to treat LS and they warrant further clinical translation. This study also provides the first evidence that ultrasound-assisted gene replacement can exert a therapeutic effect in a condition affecting the central nervous system.

Open article ↗



cell therapies
2026-08-01 | Engineering mitochondrial delivery for efficient and precise mitochondrial transplantation

Mitochondrial dysfunction constitutes a shared pathological basis for a broad spectrum of major diseases, including primary mitochondrial disorders, neurodegenerative diseases, cardiovascular and cerebrovascular diseases, and agingassociated tissue degeneration [1].In inherited mitochondrial diseases, such as Leigh syndrome and mitochondrial DNA depletion syndromes, defects in mitochondrial DNA

Open article ↗



2026-05-25 | Metabolic Reprogramming and Exosome Remodeling in an Ndufs4 ‐Deficient Model of Leigh Syndrome

ABSTRACT Leigh syndrome is a severe neurometabolic disorder with an incompletely understood pathogenesis. This study investigated the role of Ndufs4 knockout in Leigh syndrome by exploring its impact on cellular metabolism and exosome biology. Initially, we observed that homozygous knockout ( Ndufs4 −/− ) mice exhibited significantly reduced body size and spleen weight compared to wild‐type ( Ndufs4 +/+ ) controls, although the spleen index remained unchanged. Notably, the brain index was significantly increased. Histological analysis revealed structural abnormalities in brain tissue, accompanied by elevated expression of the astrocytic marker GFAP, both in vivo and in differentiated neural stem cells (NSCs), indicating a neuropathological effect of Ndufs4 knockout. Metabolically, Ndufs4 knockout in NSCs did not reduce ATP levels but increased reactive oxygen species (ROS) levels, enhanced glucose uptake (2‐NBDG), and decreased mitochondrial membrane potential (JC‐1). Concurrent shifts in metabolites—decreased L‐lactate, increased acetyl‐CoA, and a lower NADP + /NADPH ratio—implied a potential redirection of metabolic flux toward the pentose phosphate pathway. Furthermore, although the total exosome concentration was reduced in Ndufs4 −/− mice, the protein content per exosome was significantly elevated, indicating enhanced protein loading per vesicle. Proteomic profiling of brain‐derived exosomes identified increased levels of flotillin‐1 and Slc6a5, proteins associated with the mTOR pathway. Consistent with this, downstream mTOR signaling (Phospho‐S6 Ribosomal Protein (Ser235/236; p‐RPS6) and Phospho‐p70 S6 kinase (Thr389; p‐p70S6K)) was substantially attenuated in Ndufs4 −/− mice, indicating suppression of the mTOR pathway. Together, these results elucidate novel mechanisms through which Ndufs4 knockout drives exosomal remodeling, reprograms cellular metabolism, and suppresses mTOR signaling, providing a conceptual framework for understanding Leigh syndrome pathogenesis and informing therapeutic development.

Open article ↗



2026-03-20 | Transplantation of encapsulated mitochondria alleviates dysfunction in mitochondrial and Parkinson's disease models.

Mitochondrial transplantation holds significant potential for the treatment of mitochondrial diseases. However, how to efficiently deliver exogenous mitochondria to somatic cells or tissues remains unresolved. We present a mitochondrial transplantation approach to deliver mitochondria into the cells and tissues of mice and monkeys with high efficiency, based on encapsulating mitochondria with vesicles derived from the plasma membrane of erythrocytes. Treatment with encapsulated mitochondria complemented the loss, deletion, or mutation of mitochondrial DNA, thereby rescuing the associated bioenergetic and biochemical defects in patient-derived cells with mitochondrial disorders. Furthermore, mitochondrial capsules rescued the mitochondrial DNA depletion syndrome and Leigh syndrome in Dguok-/- and Ndufs4-/- mouse models, respectively. Moreover, in a mouse model of Parkinson's disease, mitochondrial capsules rescued neuron loss, improved motor skills, and restored mitochondrial function in the affected brain regions. Our study demonstrates the potential of this mitochondrial capsule as a treatment for mitochondrial disorders and proposes an "organelle therapy" strategy in regenerative medicine.

Open article ↗



2025-01-09 | [Study of the feasibility of polar body transfer combined with preimplantation genetic testing for blocking the intergenerational transmission of mitochondrial genetic diseases].

To assess the feasibility of first polar body transfer (PB1T) combined with preimplantation mitochondrial genetic testing for blocking the transmission of a pathogenic mitochondrial DNA 8993T>G mutation. A Chinese family affected with Leigh syndrome which had attended the Reproductive Medicine Centre of the First Affiliated Hospital of Anhui Medical University in September 2021 was selected as the study subject. Controlled ovarian hyperstimulation was carried out for the proband after completing the detection of the mitochondrial DNA 8993T>G mutation load among the pedigree members. Mature MII oocytes were inseminated by intracytoplasmic sperm injection (ICSI), cultured in vitro for 5 to 6 days to the blastocyst stage, and trophoblastocytes were obtained by microbiopsy. Mitochondrial DNA testing (PGT-MT) and chromosomal aneuploidy (PGT-A) analyses were carried out after whole-genome amplification, and the embryos with zero mutation load were selected for transfer. Amniotic fluid and umbilical cord blood samples were collected during middle pregnancy and after birth respectively for mitochondrial DNA testing to verify the reliability of embryo screening. As an attempt, PB1 with good morphology of MII oocytes was selected for transfer into the enucleated oocytoplasm from healthy donors, followed by ICSI fertilization, blastocyst culture and PGT of embryos using the same procedure. This study has been approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University (No. 2021zhyx-B12). An antagonist protocol was used for ovarian stimulation, and a total of 19 oocytes were obtained, of which 14 MII were fertilized by ICSI, and 2 had developed into blastocysts. PGT-MT was carried out on biopsied trophoblastocytes, in which the mitochondrial DNA 8993T>G mutation load was not detected in one embryo, the other was 100% mutated, and the mutation loads of the remaining unfertilized eggs and developmentally arrested embryos ranged from 0% ~ 100%, presenting a clear biased distribution. With fully informed consent, one PGT-MT zero mutation load blastocyst was transferred and clinical pregnancy was achieved. Mitochondrial DNA and chromosomal testing of amniotic fluid cells during middle pregnancy had revealed no abnormalities. The proband had delivered a healthy boy through Caesarean section at 39+5 weeks of gestation, and no mutation was detected in the cord blood sample. Five well-formed PBs from 14 eggs were selected for PB1 transfer, followed by ICSI and culture, and two of the reconstituted embryos had formed blastocysts, with none of the above mutations detected in the biopsied samples. The PGT-MT technology can help families affected with mitochondrial diseases to have healthy offspring. PB1 transfer in combination with ICSI and PGT-MT holds the promise of turning waste into treasure and providing an alternative means of fertility for such families.

Open article ↗



2024-09-03 | Mitochondria transfer-based therapies reduce the morbidity and mortality of Leigh syndrome.

Mitochondria transfer is a recently described phenomenon in which donor cells deliver mitochondria to acceptor cells1-3. One possible consequence of mitochondria transfer is energetic support of neighbouring cells; for example, exogenous healthy mitochondria can rescue cell-intrinsic defects in mitochondrial metabolism in cultured ρ0 cells or Ndufs4-/- peritoneal macrophages4-7. Exposing haematopoietic stem cells to purified mitochondria before autologous haematopoietic stem cell transplantation allowed for treatment of anaemia in patients with large-scale mitochondrial DNA mutations8,9, and mitochondria transplantation was shown to minimize ischaemic damage to the heart10-12, brain13-15 and limbs16. However, the therapeutic potential of using mitochondria transfer-based therapies to treat inherited mitochondrial diseases is unclear. Here we demonstrate improved morbidity and mortality of the Ndufs4-/- mouse model of Leigh syndrome (LS) in multiple treatment paradigms associated with mitochondria transfer. Transplantation of bone marrow from wild-type mice, which is associated with release of haematopoietic cell-derived extracellular mitochondria into circulation and transfer of mitochondria to host cells in multiple organs, ameliorates LS in mice. Furthermore, administering isolated mitochondria from wild-type mice extends lifespan, improves neurological function and increases energy expenditure of Ndufs4-/- mice, whereas mitochondria from Ndufs4-/- mice did not improve neurological function. Finally, we demonstrate that cross-species administration of human mitochondria to Ndufs4-/- mice also improves LS. These data suggest that mitochondria transfer-related approaches can be harnessed to treat mitochondrial diseases, such as LS.

Open article ↗



other
2026-02-04 | Leigh Syndrome Pathomechanism Involves Region-Specific Innate Immune Activation in Ndufs4 Knockout Mice.

Although recent evidence suggests that the immune system contributes to the pathogenesis of paediatric Leigh syndrome, detailed mechanistic insights are still lacking. Here, we investigated the involvement of immune system activation and inflammation in brain tissue in Leigh syndrome, using hypothesis generating methods. We compared the transcriptomes of olfactory bulb and cerebellum from male Ndufs4−/− (knockout) mice (n = 5–6), a well-established model of paediatric Leigh syndrome. Relative to wildtype animals, knockout mice displayed enrichment of innate immune system pathways in the olfactory bulb. Unexpectedly, relative to the olfactory bulb, few pathways were enriched in the cerebellum, and none that indicated similar changes to the immune system. Innate immune system pathways in the olfactory bulb were mainly upregulated and included a large set of interferon stimulated genes, and genes involved in JAK-STAT and retinoic acid-inducible gene 1-like signalling, interleukins, interferon receptors and endogenous double strand RNA sensors. We propose that innate immune system activation starts in the olfactory bulb, is mediated by the retinoic acid-inducible gene 1-like signalling pathway in response to increased cytosolic double-strand RNA, leading to chemokines that recruit leukocytes to other brain regions to elicit an immune response. Our results fill in the gap between mitochondrial dysfunction and activation of the innate immune response, which has been reported by others. Our findings strongly suggest that immune system activation constitutes part of the Leigh syndrome pathomechanism, which is compatible with the improvement observed in mitochondrial disease patients following immune system-targeting interventions.

Open article ↗



2024-04-29 | Interferon-gamma contributes to disease progression in the Ndufs4(-/-) model of Leigh syndrome.

Leigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi-system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the Ndufs4(-/-) mouse model of LS: treatment of Ndufs4(-/-) mice with the macrophage-depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon-gamma (IFNγ) and interferon gamma-induced protein 10 (IP10) were found to be significantly elevated in Ndufs4(-/-) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS. To establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient Ndufs4(-/-)/Ifng(-/-) and Ndufs4(-/-)/IP10(-/-) double knockout animals, as well as IFNγ and IP10 heterozygous, Ndufs4(-/-)/Ifng(+/-) and Ndufs4(-/-)/IP10(+/-), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS. Loss of IP10 does not significantly impact the onset or progression of disease in the Ndufs4(-/-) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage-dependent manner, though the benefits are modest compared to Csf1r inhibition. IFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.

Open article ↗



2023-07-10 | IFNγ modestly contributes to disease progression in theNdufs4(-/-) model of Leigh syndrome while IP10 is dispensable

Abstract Leigh syndrome (LS) is the most common pediatric presentation of genetic mitochondrial disease. LS is a multi-system disease characterized by severe neurologic and metabolic abnormalities. The defining feature of the disease is the presence of symmetric, bilateral, progressive necrotizing lesions in the brain stem, cerebellum, and basal ganglia. The pathogenic mechanisms underlying disease initiation and progression in LS have yet to be elucidated. Recent evidence demonstrates that the immune system plays a key role in LS pathogenesis. Treatment with the macrophage-depleting Csf1r inhibitor pexidartinib prevents disease in the Ndufs4 (-/-) mouse model of LS, but the mechanisms leading to immune activation and governing disease progression remain to be elucidated. In recent work, the cytokines IFNγ and IFNγ-induced protein 10 (IP10) were found to be significantly elevated in Ndufs4 (-/-) brainstem. Given their role as macrophage-activating factors, here we sought to assess the role of IFNγ and IP10 in LS using by generating Ndufs4 (-/-)/ Ifng (-/-) and Ndufs4 (-/-)/ IP10 (-/-) double knockout lines. We find that IP10 alone does not significantly impact the onset or progression of disease in the Ndufs4 (-/-) model, while IFNγ loss significantly, but modestly, improves survival. These data indicate that IFNγ contributes to pathology, but that IFNγ and IP10 are both dispensable for overall disease course of LS. Our findings support some role for IFNγ targeting therapies in the management of mitochondrial disease, but suggest they may provide only modest benefits, at least in LS.

Open article ↗



2023-02-03 | PET117 Modulates Mitochondrial-encoded COX1 Translation by stabilizing TACO1

Abstract Mitochondria are the most important organelles in energy metabolism. Complexes of the mitochondrial oxidative phosphorylation system (OXPHOS) are formed by proteins of dual origin synthesized in the cytosol or mitochondria. The mechanisms underlying specific translation by mitoribosomes in mammals are largely unknown. Here, we report a chaperone protein of cytochrome c oxidase (COX) assembly, PET117 plays a critical role in the synthesis of mitochondrial-encoded COX1 protein in human cells. Lack of PET117 impaired mitochondrial function via suppression of mitochondrial oxygen consumption rate (OCR), probably due to reduced stability of TACO1, a COX1 translational activator. We uncovered the role of PET117 in mitochondrial regulation and a novel PET117-TACO1 axis modulating mitochondrial gene expression.

Open article ↗



2022-09-08 | The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence.

Genetic mitochondrial diseases represent a significant challenge to human health. These diseases are extraordinarily heterogeneous in clinical presentation and genetic origin, and often involve multi-system disease with severe progressive symptoms. Mitochondrial diseases represent the most common cause of inherited metabolic disorders and one of the most common causes of inherited neurologic diseases, yet no proven therapeutic strategies yet exist. The basic cell and molecular mechanisms underlying the pathogenesis of mitochondrial diseases have not been resolved, hampering efforts to develop therapeutic agents. In recent pre-clinical work, we have shown that pharmacologic agents targeting the immune system can prevent disease in the Ndufs4(KO) model of Leigh syndrome, indicating that the immune system plays a causal role in the pathogenesis of at least this form of mitochondrial disease. Intriguingly, a number of case reports have indicated that immune-targeting therapeutics may be beneficial in the setting of genetic mitochondrial disease. Here, we summarize clinical and pre-clinical evidence suggesting a key role for the immune system in mediating the pathogenesis of at least some forms of genetic mitochondrial disease. Significant clinical and pre-clinical evidence indicates a key role for the immune system as a significant in the pathogenesis of at least some forms of genetic mitochondrial disease.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

10 orphan drug designations for Leigh syndrome.

10 orphan drug designations for Leigh syndrome.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

adeno-associated virus 9 human NADH:ubiquinone oxidoreductase subunit S4

gene therapies

FDA
2024-10-22

—

National Human Genome Research Institute (NHGRI), National Institutes of Health (NIH)

2-((hydroxy((R)-2-(((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl)oxy)-3-(((E)-octadec-2-en-1-yl)oxy)propoxy)phosphoryl)oxy)ethan-1-ammonium

small molecules

FDA
2024-09-26

—

Institute of Rheological Functions of Food

Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate

small molecules

EMA
2023-12-13

—

Pharming Technologies B.V.

Sildenafil citrate

small molecules

EMA
2023-10-13

—

Charite Universitaetsmedizin Berlin KöR

Cannabidiol

small molecules

EMA
2023-07-25

—

Universitat Autònoma De Barcelona

Adeno-associated viral vector serotype 9 containing the human SURF1 gene

gene therapies

EMA
2021-11-12

—

Raremoon Consulting Esp S.L.

TGTX-102, an adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human SURF1 protein.

gene therapies

FDA
2020-10-20

—

University of Texas Southwestern Medical Center

Sonlicromanol hydrochloride [KH-176]

small molecules

EMA
2014-10-15

Phase III
Ongoing

Khondrion B.V.

vatiquinone

small molecules

FDA
2014-06-04

Phase III
Completed

PTC Therapeutics, Inc.

Vatiquinone

small molecules

EMA
2011-12-09

Phase II/III
Terminated

PTC Therapeutics International Limited

“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.